The Society of Cardiovascular Computed Tomography (SCCT) Global Meeting 2025, held in Amsterdam on February 6-7, 2025, brought together leading experts to discuss advancements in cardiovascular CT technologies. A highlight of the event was the “Industry Session: Cutting Edge CT Technologies,” chaired by Dr. Eric Williamson and Dr. Koen Nieman. This session featured presentations from several industry leaders, including HeartFlow, Circle Cardiovascular Imaging, Philips, Siemens Healthineers AG, and Keya Medical.
During this session, Dr. Irfan Shafique, MD, representing Keya Medical, delivered a compelling presentation titled “AI in CTFFR Analysis.” Dr. Shafique, a renowned radiologist with extensive expertise in cardiac imaging, focused on the application of artificial intelligence (AI) in CT-derived Fractional Flow Reserve (CTFFR) analysis. He introduced DEEPVESSEL FFR, Keya Medical’s flagship AI-driven software designed to enhance non-invasive cardiac diagnostics.
DEEPVESSEL FFR utilizes deep learning technology to perform non-invasive physiological assessments of coronary arteries using coronary computed tomography angiography (CCTA). The software processes CCTA images semi-automatically, generating a three-dimensional model of the coronary artery tree and estimating CTFFR values. This approach aims to improve the accuracy and efficiency of diagnosing coronary artery disease, potentially reducing the need for invasive procedures.
Dr. Shafique highlighted the clinical validation of DEEPVESSEL FFR, noting its FDA clearance, CE marking, NMPA clearance, and HSA certification. He emphasized how integrating AI into CTFFR analysis can lead to more precise diagnostics, better patient outcomes, and streamlined clinical workflows. The presentation underscored Keya Medical’s commitment to advancing AI-driven solutions in the field of cardiac imaging.
Case Studies – CT-FFR Analysis with DeepVessel FFR
Contact Keya Medical for more information about DEEPVESSEL FFR and collaboration opportunities.
About Dr. Irfan Shafique
Dr. Irfan Shafique, MD, is a renowned radiologist with extensive expertise in cardiac imaging. He is one of the pioneers of cardiac CTA imaging and training programs and courses at Johns Hopkins Bayview Medical Center. He is a former Johns Hopkins faculty member and co-directed cardiac CT training practicum, and he continues to teach the CME course. This most popular cardiac CT training practicum has been running for over 20 years. He has served and led many companies as CEO and CMO and serves on advisory boards (Cardiac America, Healthcare Imaging, Brexa, and Forward Healthcare Consultants).
Dr.Shafique is currently with Chesapeake Medical Imaging overseeing the Cardiac Imaging program. With a solid foundation in internal medicine and cardiology, Dr. Shafique completed postgraduate training in nuclear medicine at Johns Hopkins Medical Institutions (JHMI) in Baltimore, Maryland, and further training in radiology in Washington, DC. He is board-certified in Radiology, Nuclear Medicine, and Nuclear Cardiology and Cardiac CT.
About DEEPVESSEL FFR
DEEPVESSEL FFR is a software medical device that uses deep learning technology to perform a non-invasive physiological functional assessment of the coronary arteries using coronary computed tomography angiography (CCTA). The software processes coronary CTA images semi-automatically, generates a three-dimensional model of the coronary artery tree, and estimates CT FFR values. DEEPVESSEL FFR is FDA-Cleared, CE-Marked, NMPA-Cleared, HSA-Certified.
About Keya Medical
Keya Medical is an international medical technology company developing deep learning-based medical devices for disease diagnosis and treatment. The company is committed to creating solutions that deliver clinical value at all stages in the patient care process, covering specialties including cardiology, neurology, pulmonology, pathology, and surgery. Keya Medical has four centers of excellence in Beijing, Shanghai, Shenzhen, and Seattle. Follow us on LinkedIn, Twitter, and Facebook.
Media Contact
contact@keyamedna.com
Learn more about DEEPVESSEL FFR
We are actively looking for clinical partners in the United States and EMEA.